Comorbidity in lung cancer patients and its association with hospital readmission and fatality in China
| Autor: | Xuefeng Shi, Ping He, Yong Ma, Ruoxi Ding, Zhishui Chen, Dawei Zhu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty China Lung Neoplasms Urban Population Disease Comorbidity Malignancy Patient Readmission 03 medical and health sciences Liver disease 0302 clinical medicine Surgical oncology Internal medicine Diabetes mellitus mental disorders Genetics medicine Diabetes Mellitus Prevalence Humans Urban 030212 general & internal medicine Hospital Mortality Lung cancer RC254-282 Aged Aged 80 and over business.industry Liver Diseases Cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens Middle Aged medicine.disease Prognosis Cross-Sectional Studies Oncology 030220 oncology & carcinogenesis Hypertension Female business Administrative Claims Healthcare Research Article |
| Zdroj: | BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021) BMC Cancer |
| ISSN: | 1471-2407 |
| Popis: | Background Comorbidity has been established as one of the important predictors of poor prognosis in lung cancer. In this study, we analyzed the prevalence of main comorbidities and its association with hospital readmission and fatality for lung cancer patients in China. Methods The analyses are based on China Urban Employees’ Basic Medical insurance (UEBMI) and Urban Residents’ Basic Medical Insurance (URBMI) claims database and Hospital Information System (HIS) Database in the Beijing University Cancer Hospital in 2013–2016. We use Elixhauser Comorbidity Index to identify main types of comorbidities. Results Among 10,175 lung cancer patients, 32.2% had at least one comorbid condition, and the proportion of patients with one, two, and three or more comorbidities was 21.7, 8.3 and 2.2%, respectively. The most prevalent comorbidities identified were other malignancy (7.5%), hypertension (5.4%), pulmonary disease (3.7%), diabetes mellitus (2.5%), cardiovascular disease (2.4%) and liver disease (2.3%). The predicted probability of having comorbidity and the predicted number of comorbidities was higher for middle elderly age groups, and then decreased among patients older than 85 years. Comorbidity was positively associated with increased risk of 31-days readmission and in-hospital death. Conclusion Our study is the first to provide an overview of comorbidity among lung cancer patients in China, underlines the necessity of incorporating comorbidity in the design of screening, treatment and management of lung cancer patients in China. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|